Teriparitide update.
Teriparitide (TPD) is a novel anabolic agent that stimulates bone formation. TPD reduces risk of vertebral and nonvertebral fracture. Due to its positive effects on bone formation, many new uses of TPD are being explored. It has been studied and approved for glucocorticoid-induced osteoporosis. Many questions about the use of TPD remain including use of follow-up therapy, combination therapy, sequential therapy, and its potential role in fracture healing and treatment of back pain related to osteoporosis.
Cedars-Sinai Bone Center of Excellence, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA 90211, USA. stuarts@omcresearch.org
Stuart L
SL
Silverman
Keaton
K
Nasser
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000453:epidemiology; D012307:Risk Factors; D019379:Teriparatide / Q000627:therapeutic use*; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D019379:Teriparatide; D000077211:Zoledronic Acid